Biogen Idec Inc (BIIB)
In November 2003, Biogen and IDEC Pharmaceuticals finalised their $6bn merger, creating Biogen Idec, the third-largest biotechnology company in the world. The company is now a global leader in the development, manufacturing, and commercialisation of novel therapies. Its major products include treatments for relapsing multiple sclerosis, certain B-cell non-Hodgkin's lymphomas and adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
From their web site: "Biogen Idec does not pay a dividend..."
- Pharmaceuticals & Biotechnology
- 🇺🇸 United States
- $320.14 yesterday's close
52 Week High0.0%13 December 2018
52 Week Low0.0%13 December 2018
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
Biogen Idec Inc optimized dividend - 12 month history
Biogen Idec Inc share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: